<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02465866</url>
  </required_header>
  <id_info>
    <org_study_id>CLCT-004</org_study_id>
    <nct_id>NCT02465866</nct_id>
  </id_info>
  <brief_title>A Four-Period, Four-Treatment, Four-Way Relative Bioavailability Study of CL-108 Under Fed and Fasted Conditions</brief_title>
  <official_title>A Single-Dose, Four-Period, Four-Treatment, Four-Way Crossover Relative Bioavailability Study of CL-108 Under Fed and Fasted Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charleston Laboratories, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charleston Laboratories, Inc</source>
  <brief_summary>
    <textblock>
      This study will compare the relative bioavailability of hydrocodone, acetaminophen, and
      promethazine in CL-108 (hydrocodone 7.5mg/ acetaminophen 325 mg/ promethazine 12.5 mg)
      manufactured by Charleston Laboratories, Inc. to hydrocodone in Vicoprofen (hydrocodone 7.5
      mg /ibuprofen 200 mg), promethazine 12.5 mg, and acetaminophen in Ultracet (tramadol HCl 37.5
      mg/acetaminophen 325 mg) under fasted and fed conditions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Drug Concentration (Cmax) in Plasma Determined Directly From Individual Concentration-time Data</measure>
    <time_frame>0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, and 48 hours post-dose</time_frame>
    <description>Cmax of CL-108 and Vicoprofen + Ultracet + Phenergan were measured in the plasma (the liquid component of the blood in which the blood cells are suspended) in samples collected up to 48 hours post-dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Concentration (Tmax)</measure>
    <time_frame>0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, and 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Last Quantifiable Drug Concentration (Clast) Determined Directly From Individual Concentration-time Data</measure>
    <time_frame>0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, and 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of the Last Quantifiable Concentration (Tlast)</measure>
    <time_frame>0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, and 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed Elimination Rate Constant (λz)</measure>
    <time_frame>0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, and 48 hours post-dose</time_frame>
    <description>Estimated by linear regression through at least three data points in the terminal phase of the log concentration-time profile</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed Terminal Elimination Half-life (T1/2)</measure>
    <time_frame>0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, and 48 hours post-dose</time_frame>
    <description>Calculated as: T1/2 = ln(2)/λz</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve (AUC0-0.25) for Hydrocodone and Promethazine</measure>
    <time_frame>0 (pre-dose) to 0.25 hours post-dose</time_frame>
    <description>AUC0-0.25 measured by Linear Trapezoidal with Linear Interpolation method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-0.50 for Hydrocodone and Promethazine</measure>
    <time_frame>0 (pre-dose) to 0.5 hours post-dose</time_frame>
    <description>AUC0-0.50 measured by Linear Trapezoidal with Linear Interpolation method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-0.75 for Hydrocodone and Promethazine</measure>
    <time_frame>0 (Pre-dose) to 0.75 hours post-dose</time_frame>
    <description>AUC0-0.75 measured by Linear Trapezoidal with Linear Interpolation method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-1.0 for Hydrocodone and Promethazine</measure>
    <time_frame>0 (pre-dose) to 1.0 hours post-dose</time_frame>
    <description>AUC0-1.0 measured by Linear Trapezoidal with Linear Interpolation method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-1.5 for Hydrocodone and Promethazine</measure>
    <time_frame>0 (pre-dose) to 1.5 hours post-dose</time_frame>
    <description>AUC0-1.5 measured by Linear Trapezoidal with Linear Interpolation method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-2.0 for Hydrocodone and Promethazine</measure>
    <time_frame>0 (pre-dose) to 2 hours post-dose</time_frame>
    <description>AUC0-2.0 measured by Linear Trapezoidal with Linear Interpolation method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-4.0 for Hydrocodone and Promethazine</measure>
    <time_frame>0 (pre-dose) to 4 hours post-dose</time_frame>
    <description>AUC0-4.0 measured by Linear Trapezoidal with Linear Interpolation method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time (AUClast) Curve From Time-zero to the Time of the Last Quantifiable Concentration</measure>
    <time_frame>0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, and 48 hours post-dose</time_frame>
    <description>Calculated using the linear trapezoidal rule</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time (AUCinf) Curve From Time-zero Extrapolated to Infinity</measure>
    <time_frame>0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, and 48 hours post-dose</time_frame>
    <description>Calculated as:
AUCinf = AUClast + Clast/λz</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of AUCinf [AUCExtrap (%)] Based on Extrapolation</measure>
    <time_frame>0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, and 48 hours post-dose</time_frame>
    <description>Calculated as:
AUCExtrap (%) = (AUC0-inf - AUC0-last)/AUC0-inf *100</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment A: CL-108 (Fasted)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fasted condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B: CL-108 (Fed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fed condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C: Vicoprofen, Ultracet and Phenergan (Fasted)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fasted condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D: Vicoprofen, Ultracet and Phenergan (Fed)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fed condition</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CL-108</intervention_name>
    <description>Hydrocodone bitartrate/acetaminophen/promethazine 7.5 mg/325 mg/12.5 mg single dose by mouth</description>
    <arm_group_label>Treatment A: CL-108 (Fasted)</arm_group_label>
    <arm_group_label>Treatment B: CL-108 (Fed)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vicoprofen</intervention_name>
    <description>Hydrocodone Bitartrate and Ibuprofen 7.5 mg/200 mg single dose tablet by mouth</description>
    <arm_group_label>Treatment C: Vicoprofen, Ultracet and Phenergan (Fasted)</arm_group_label>
    <arm_group_label>Treatment D: Vicoprofen, Ultracet and Phenergan (Fed)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ultracet</intervention_name>
    <description>Tramadol HCl/acetaminophen 37.5 mg/325 mg single dose tablet by mouth</description>
    <arm_group_label>Treatment C: Vicoprofen, Ultracet and Phenergan (Fasted)</arm_group_label>
    <arm_group_label>Treatment D: Vicoprofen, Ultracet and Phenergan (Fed)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenergan</intervention_name>
    <description>Phenergan (Promethazine HCl, USP) 12.5 mg single dose tablet by mouth</description>
    <arm_group_label>Treatment C: Vicoprofen, Ultracet and Phenergan (Fasted)</arm_group_label>
    <arm_group_label>Treatment D: Vicoprofen, Ultracet and Phenergan (Fed)</arm_group_label>
    <other_name>Promethazine HCl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Subject's body mass index (BMI) must be between 18 and 30kg/m2 (inclusive), and
             subject must weigh a minimum of 50 kg (110lb)

          -  Abide by study restrictions

          -  Acceptable birth control measures

          -  Ability to attend all study visits

          -  Vital signs as per protocol

          -  Willing to consume high calorie meals within designated time frame

        Exclusion Criteria:

          -  Clinically significant medical history

          -  Clinically significant abnormal findings

          -  History or presence of allergic or adverse response to hydrocodone,
             ibuprofen,acetaminophen, any non-steroidal anti-inflammatory drugs (NSAIDs),
             promethazine, or related drugs.

          -  Has smoked or used tobacco products within 60 days prior to the first dose of study
             medication

          -  Has donated blood or plasma within 30 days prior to the first dose of study medication

          -  Has participated in another clinical trial (randomized subjects only) within 30 days
             prior to the first dose of study medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2015</study_first_submitted>
  <study_first_submitted_qc>June 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2015</study_first_posted>
  <results_first_submitted>November 14, 2016</results_first_submitted>
  <results_first_submitted_qc>January 27, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 20, 2017</results_first_posted>
  <last_update_submitted>March 30, 2017</last_update_submitted>
  <last_update_submitted_qc>March 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charleston Laboratories, Inc</investigator_affiliation>
    <investigator_full_name>Joseph Hazelton</investigator_full_name>
    <investigator_title>Vice-President, Regulatory Affairs</investigator_title>
  </responsible_party>
  <keyword>Plasma concentration</keyword>
  <keyword>Time to plasma concentration</keyword>
  <keyword>Elimination rate constant</keyword>
  <keyword>Elimination half life</keyword>
  <keyword>Area under the curve</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocodone</mesh_term>
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Twenty healthy subjects were enrolled in the study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence 1: ABDC</title>
          <description>Treatment A: CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fasted condition
Treatment B: CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fed condition
Treatment D: Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fed condition
Treatment C: Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fasted condition
Dosing in 4 study periods was separated by a 14-day washout period</description>
        </group>
        <group group_id="P2">
          <title>Sequence 2: BCAD</title>
          <description>Treatment B: CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fed condition
Treatment C: Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fasted condition
Treatment A: CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fasted condition
Treatment D: Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fed condition
Dosing in 4 study periods was separated by a 14-day washout period</description>
        </group>
        <group group_id="P3">
          <title>Sequence 3: CDBA</title>
          <description>Treatment C: Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fasted condition
Treatment D: Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fed condition
Treatment B: CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fed condition
Treatment A: CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fasted condition
Dosing in 4 study periods was separated by a 14-day washout period</description>
        </group>
        <group group_id="P4">
          <title>Sequence 4: DACB</title>
          <description>Treatment D: Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fed condition
Treatment A: CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fasted condition
Treatment C: Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fasted condition
Treatment B: CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fed condition
Dosing in 4 study periods was separated by a 14-day washout period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 1: Washout (14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2: Washout (14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 3: Washout (14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 4: Washout (14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Subjects</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.85" spread="17.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="163.15" spread="10.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.83" spread="10.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m²</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.43" spread="2.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Drug Concentration (Cmax) in Plasma Determined Directly From Individual Concentration-time Data</title>
        <description>Cmax of CL-108 and Vicoprofen + Ultracet + Phenergan were measured in the plasma (the liquid component of the blood in which the blood cells are suspended) in samples collected up to 48 hours post-dose.</description>
        <time_frame>0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, and 48 hours post-dose</time_frame>
        <population>Intended to treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: CL-108 (Fasted)</title>
            <description>CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fasted condition</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: CL-108 (Fed)</title>
            <description>CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fed condition</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: Vicoprofen, Ultracet and Phenergan (Fasted)</title>
            <description>Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fasted condition</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: Vicoprofen, Ultracet and Phenergan (Fed)</title>
            <description>Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Drug Concentration (Cmax) in Plasma Determined Directly From Individual Concentration-time Data</title>
          <description>Cmax of CL-108 and Vicoprofen + Ultracet + Phenergan were measured in the plasma (the liquid component of the blood in which the blood cells are suspended) in samples collected up to 48 hours post-dose.</description>
          <population>Intended to treat (ITT) population</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hydrocodone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" spread="5.48"/>
                    <measurement group_id="O2" value="17.9" spread="5.80"/>
                    <measurement group_id="O3" value="18.4" spread="5.62"/>
                    <measurement group_id="O4" value="17.5" spread="3.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acetaminophen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.71" spread="1.49"/>
                    <measurement group_id="O2" value="3.27" spread="1.00"/>
                    <measurement group_id="O3" value="5.02" spread="1.66"/>
                    <measurement group_id="O4" value="3.03" spread="0.919"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Promethazine (Number of Participants=19,19,20,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.79" spread="3.75"/>
                    <measurement group_id="O2" value="3.66" spread="2.16"/>
                    <measurement group_id="O3" value="4.35" spread="2.94"/>
                    <measurement group_id="O4" value="4.08" spread="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach Maximum Concentration (Tmax)</title>
        <time_frame>0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, and 48 hours post-dose</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: CL-108 (Fasted)</title>
            <description>CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fasted condition</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: CL-108 (Fed)</title>
            <description>CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fed condition</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: Vicoprofen, Ultracet and Phenergan (Fasted)</title>
            <description>Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fasted condition</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: Vicoprofen, Ultracet and Phenergan (Fed)</title>
            <description>Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Concentration (Tmax)</title>
          <population>ITT population</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hydrocodone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.55" spread="0.71"/>
                    <measurement group_id="O2" value="3.38" spread="1.58"/>
                    <measurement group_id="O3" value="1.39" spread="1.22"/>
                    <measurement group_id="O4" value="3.09" spread="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acetaminophen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" spread="0.44"/>
                    <measurement group_id="O2" value="2.84" spread="1.49"/>
                    <measurement group_id="O3" value="0.80" spread="0.55"/>
                    <measurement group_id="O4" value="2.64" spread="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Promethazine (Number of Participants=19,19,20,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.35" spread="1.37"/>
                    <measurement group_id="O2" value="5.24" spread="2.37"/>
                    <measurement group_id="O3" value="4.90" spread="1.72"/>
                    <measurement group_id="O4" value="6.45" spread="4.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Last Quantifiable Drug Concentration (Clast) Determined Directly From Individual Concentration-time Data</title>
        <time_frame>0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, and 48 hours post-dose</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: CL-108 (Fasted)</title>
            <description>CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fasted condition</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: CL-108 (Fed)</title>
            <description>CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fed condition</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: Vicoprofen, Ultracet and Phenergan (Fasted)</title>
            <description>Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fasted condition</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: Vicoprofen, Ultracet and Phenergan (Fed)</title>
            <description>Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>Last Quantifiable Drug Concentration (Clast) Determined Directly From Individual Concentration-time Data</title>
          <population>ITT population</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hydrocodone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.556" spread="0.354"/>
                    <measurement group_id="O2" value="0.523" spread="0.412"/>
                    <measurement group_id="O3" value="0.465" spread="0.315"/>
                    <measurement group_id="O4" value="0.527" spread="0.424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acetaminophen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0741" spread="0.0297"/>
                    <measurement group_id="O2" value="0.0917" spread="0.0378"/>
                    <measurement group_id="O3" value="0.0724" spread="0.0291"/>
                    <measurement group_id="O4" value="0.0907" spread="0.0428"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Promethazine (Number of Participants=19,19,20,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.611" spread="0.936"/>
                    <measurement group_id="O2" value="0.586" spread="1.04"/>
                    <measurement group_id="O3" value="0.574" spread="0.829"/>
                    <measurement group_id="O4" value="0.701" spread="0.912"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time of the Last Quantifiable Concentration (Tlast)</title>
        <time_frame>0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, and 48 hours post-dose</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: CL-108 (Fasted)</title>
            <description>CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fasted condition</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: CL-108 (Fed)</title>
            <description>CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fed condition</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: Vicoprofen, Ultracet and Phenergan (Fasted)</title>
            <description>Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fasted condition</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: Vicoprofen, Ultracet and Phenergan (Fed)</title>
            <description>Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>Time of the Last Quantifiable Concentration (Tlast)</title>
          <population>ITT population</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hydrocodone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.80" spread="8.99"/>
                    <measurement group_id="O2" value="31.21" spread="11.28"/>
                    <measurement group_id="O3" value="28.81" spread="9.84"/>
                    <measurement group_id="O4" value="31.58" spread="11.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acetaminophen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.38" spread="2.76"/>
                    <measurement group_id="O2" value="24.01" spread="0.04"/>
                    <measurement group_id="O3" value="23.41" spread="2.69"/>
                    <measurement group_id="O4" value="24.01" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Promethazine (Number of Participants=19,19,20,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.76" spread="5.51"/>
                    <measurement group_id="O2" value="46.77" spread="5.52"/>
                    <measurement group_id="O3" value="46.81" spread="5.37"/>
                    <measurement group_id="O4" value="46.74" spread="5.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Observed Elimination Rate Constant (λz)</title>
        <description>Estimated by linear regression through at least three data points in the terminal phase of the log concentration-time profile</description>
        <time_frame>0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, and 48 hours post-dose</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: CL-108 (Fasted)</title>
            <description>CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fasted condition</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: CL-108 (Fed)</title>
            <description>CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fed condition</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: Vicoprofen, Ultracet and Phenergan (Fasted)</title>
            <description>Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fasted condition</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: Vicoprofen, Ultracet and Phenergan (Fed)</title>
            <description>Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Elimination Rate Constant (λz)</title>
          <description>Estimated by linear regression through at least three data points in the terminal phase of the log concentration-time profile</description>
          <population>ITT population</population>
          <units>h-1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hydrocodone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1468" spread="0.0293"/>
                    <measurement group_id="O2" value="0.1373" spread="0.0258"/>
                    <measurement group_id="O3" value="0.1415" spread="0.0292"/>
                    <measurement group_id="O4" value="0.1371" spread="0.0271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acetaminophen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1577" spread="0.0310"/>
                    <measurement group_id="O2" value="0.1359" spread="0.0223"/>
                    <measurement group_id="O3" value="0.1600" spread="0.0355"/>
                    <measurement group_id="O4" value="0.1412" spread="0.0218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Promethazine (Number of Participants=19,18,20,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0429" spread="0.0129"/>
                    <measurement group_id="O2" value="0.0451" spread="0.0451"/>
                    <measurement group_id="O3" value="0.0422" spread="0.0120"/>
                    <measurement group_id="O4" value="0.0458" spread="0.0145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Observed Terminal Elimination Half-life (T1/2)</title>
        <description>Calculated as: T1/2 = ln(2)/λz</description>
        <time_frame>0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, and 48 hours post-dose</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: CL-108 (Fasted)</title>
            <description>CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fasted condition</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: CL-108 (Fed)</title>
            <description>CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fed condition</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: Vicoprofen, Ultracet and Phenergan (Fasted)</title>
            <description>Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fasted condition</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: Vicoprofen, Ultracet and Phenergan (Fed)</title>
            <description>Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Terminal Elimination Half-life (T1/2)</title>
          <description>Calculated as: T1/2 = ln(2)/λz</description>
          <population>ITT population</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hydrocodone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.93" spread="1.11"/>
                    <measurement group_id="O2" value="5.22" spread="0.99"/>
                    <measurement group_id="O3" value="5.13" spread="1.18"/>
                    <measurement group_id="O4" value="5.26" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acetaminophen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.59" spread="1.06"/>
                    <measurement group_id="O2" value="5.22" spread="0.79"/>
                    <measurement group_id="O3" value="4.52" spread="0.93"/>
                    <measurement group_id="O4" value="5.03" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Promethazine (Number of Participants=19,18,20,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.49" spread="5.21"/>
                    <measurement group_id="O2" value="15.95" spread="3.04"/>
                    <measurement group_id="O3" value="17.77" spread="5.57"/>
                    <measurement group_id="O4" value="16.24" spread="4.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve (AUC0-0.25) for Hydrocodone and Promethazine</title>
        <description>AUC0-0.25 measured by Linear Trapezoidal with Linear Interpolation method.</description>
        <time_frame>0 (pre-dose) to 0.25 hours post-dose</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: CL-108 (Fasted)</title>
            <description>CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fasted condition</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: CL-108 (Fed)</title>
            <description>CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fed condition</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: Vicoprofen, Ultracet and Phenergan (Fasted)</title>
            <description>Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fasted condition</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: Vicoprofen, Ultracet and Phenergan (Fed)</title>
            <description>Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve (AUC0-0.25) for Hydrocodone and Promethazine</title>
          <description>AUC0-0.25 measured by Linear Trapezoidal with Linear Interpolation method.</description>
          <population>ITT population</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hydrocodone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08870" spread="0.1318"/>
                    <measurement group_id="O2" value="0.03786" spread="0.1269"/>
                    <measurement group_id="O3" value="0.1219" spread="0.2151"/>
                    <measurement group_id="O4" value="0.02250" spread="0.04577"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Promethazine (Number of Participants=19,19,20,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01086" spread="0.03169"/>
                    <measurement group_id="O2" value="0.003941" spread="0.01413"/>
                    <measurement group_id="O3" value="0.006288" spread="0.02608"/>
                    <measurement group_id="O4" value="0.002612" spread="0.01138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-0.50 for Hydrocodone and Promethazine</title>
        <description>AUC0-0.50 measured by Linear Trapezoidal with Linear Interpolation method.</description>
        <time_frame>0 (pre-dose) to 0.5 hours post-dose</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: CL-108 (Fasted)</title>
            <description>CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fasted condition</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: CL-108 (Fed)</title>
            <description>CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fed condition</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: Vicoprofen, Ultracet and Phenergan (Fasted)</title>
            <description>Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fasted condition</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: Vicoprofen, Ultracet and Phenergan (Fed)</title>
            <description>Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-0.50 for Hydrocodone and Promethazine</title>
          <description>AUC0-0.50 measured by Linear Trapezoidal with Linear Interpolation method.</description>
          <population>ITT population</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hydrocodone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9532" spread="0.9498"/>
                    <measurement group_id="O2" value="0.2566" spread="0.6382"/>
                    <measurement group_id="O3" value="1.280" spread="1.271"/>
                    <measurement group_id="O4" value="0.3163" spread="0.4305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Promethazine (Number of Participants=19,19,20,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03535" spread="0.06239"/>
                    <measurement group_id="O2" value="0.01570" spread="0.03508"/>
                    <measurement group_id="O3" value="0.02692" spread="0.06096"/>
                    <measurement group_id="O4" value="0.01220" spread="0.02452"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-0.75 for Hydrocodone and Promethazine</title>
        <description>AUC0-0.75 measured by Linear Trapezoidal with Linear Interpolation method.</description>
        <time_frame>0 (Pre-dose) to 0.75 hours post-dose</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: CL-108 (Fasted)</title>
            <description>CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fasted condition</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: CL-108 (Fed)</title>
            <description>CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fed condition</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: Vicoprofen, Ultracet and Phenergan (Fasted)</title>
            <description>Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fasted condition</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: Vicoprofen, Ultracet and Phenergan (Fed)</title>
            <description>Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-0.75 for Hydrocodone and Promethazine</title>
          <description>AUC0-0.75 measured by Linear Trapezoidal with Linear Interpolation method.</description>
          <population>ITT population</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hydrocodone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.194" spread="2.379"/>
                    <measurement group_id="O2" value="0.8759" spread="1.645"/>
                    <measurement group_id="O3" value="4.027" spread="3.092"/>
                    <measurement group_id="O4" value="1.276" spread="1.629"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Promethazine (Number of Participants=19,19,20,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1108" spread="0.1090"/>
                    <measurement group_id="O2" value="0.05549" spread="0.08128"/>
                    <measurement group_id="O3" value="0.09690" spread="0.1478"/>
                    <measurement group_id="O4" value="0.04610" spread="0.06227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-1.0 for Hydrocodone and Promethazine</title>
        <description>AUC0-1.0 measured by Linear Trapezoidal with Linear Interpolation method.</description>
        <time_frame>0 (pre-dose) to 1.0 hours post-dose</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: CL-108 (Fasted)</title>
            <description>CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fasted condition</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: CL-108 (Fed)</title>
            <description>CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fed condition</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: Vicoprofen, Ultracet and Phenergan (Fasted)</title>
            <description>Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fasted condition</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: Vicoprofen, Ultracet and Phenergan (Fed)</title>
            <description>Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-1.0 for Hydrocodone and Promethazine</title>
          <description>AUC0-1.0 measured by Linear Trapezoidal with Linear Interpolation method.</description>
          <population>ITT population</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hydrocodone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.383" spread="3.637"/>
                    <measurement group_id="O2" value="2.046" spread="3.244"/>
                    <measurement group_id="O3" value="7.524" spread="4.678"/>
                    <measurement group_id="O4" value="2.722" spread="3.329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Promethazine (Number of Participants=19,19,20,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2578" spread="0.1999"/>
                    <measurement group_id="O2" value="0.1457" spread="0.1649"/>
                    <measurement group_id="O3" value="0.2311" spread="0.3055"/>
                    <measurement group_id="O4" value="0.1109" spread="0.1471"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-1.5 for Hydrocodone and Promethazine</title>
        <description>AUC0-1.5 measured by Linear Trapezoidal with Linear Interpolation method.</description>
        <time_frame>0 (pre-dose) to 1.5 hours post-dose</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: CL-108 (Fasted)</title>
            <description>CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fasted condition</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: CL-108 (Fed)</title>
            <description>CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fed condition</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: Vicoprofen, Ultracet and Phenergan (Fasted)</title>
            <description>Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fasted condition</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: Vicoprofen, Ultracet and Phenergan (Fed)</title>
            <description>Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-1.5 for Hydrocodone and Promethazine</title>
          <description>AUC0-1.5 measured by Linear Trapezoidal with Linear Interpolation method.</description>
          <population>ITT population</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hydrocodone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.33" spread="4.971"/>
                    <measurement group_id="O2" value="5.782" spread="7.049"/>
                    <measurement group_id="O3" value="14.95" spread="6.822"/>
                    <measurement group_id="O4" value="6.424" spread="6.742"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Promethazine (Number of Participants=19,19,20,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8524" spread="0.5410"/>
                    <measurement group_id="O2" value="0.5573" spread="0.4798"/>
                    <measurement group_id="O3" value="0.7330" spread="0.8395"/>
                    <measurement group_id="O4" value="0.3239" spread="0.3643"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-2.0 for Hydrocodone and Promethazine</title>
        <description>AUC0-2.0 measured by Linear Trapezoidal with Linear Interpolation method.</description>
        <time_frame>0 (pre-dose) to 2 hours post-dose</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: CL-108 (Fasted)</title>
            <description>CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fasted condition</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: CL-108 (Fed)</title>
            <description>CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fed condition</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: Vicoprofen, Ultracet and Phenergan (Fasted)</title>
            <description>Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fasted condition</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: Vicoprofen, Ultracet and Phenergan (Fed)</title>
            <description>Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-2.0 for Hydrocodone and Promethazine</title>
          <description>AUC0-2.0 measured by Linear Trapezoidal with Linear Interpolation method.</description>
          <population>ITT population</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hydrocodone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.21" spread="6.240"/>
                    <measurement group_id="O2" value="10.95" spread="10.34"/>
                    <measurement group_id="O3" value="22.53" spread="8.183"/>
                    <measurement group_id="O4" value="11.04" spread="10.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Promethazine (Number of Participants=19,19,20,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.938" spread="1.318"/>
                    <measurement group_id="O2" value="1.267" spread="0.9936"/>
                    <measurement group_id="O3" value="1.583" spread="1.689"/>
                    <measurement group_id="O4" value="0.6735" spread="0.6328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-4.0 for Hydrocodone and Promethazine</title>
        <description>AUC0-4.0 measured by Linear Trapezoidal with Linear Interpolation method.</description>
        <time_frame>0 (pre-dose) to 4 hours post-dose</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: CL-108 (Fasted)</title>
            <description>CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fasted condition</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: CL-108 (Fed)</title>
            <description>CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fed condition</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: Vicoprofen, Ultracet and Phenergan (Fasted)</title>
            <description>Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fasted condition</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: Vicoprofen, Ultracet and Phenergan (Fed)</title>
            <description>Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-4.0 for Hydrocodone and Promethazine</title>
          <description>AUC0-4.0 measured by Linear Trapezoidal with Linear Interpolation method.</description>
          <population>ITT population</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hydrocodone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.04" spread="13.77"/>
                    <measurement group_id="O2" value="38.97" spread="18.47"/>
                    <measurement group_id="O3" value="48.35" spread="12.87"/>
                    <measurement group_id="O4" value="35.14" spread="17.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Promethazine (Number of Participants=19,19,20,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.124" spread="6.271"/>
                    <measurement group_id="O2" value="5.943" spread="3.676"/>
                    <measurement group_id="O3" value="7.101" spread="6.159"/>
                    <measurement group_id="O4" value="4.045" spread="2.497"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time (AUClast) Curve From Time-zero to the Time of the Last Quantifiable Concentration</title>
        <description>Calculated using the linear trapezoidal rule</description>
        <time_frame>0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, and 48 hours post-dose</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: CL-108 (Fasted)</title>
            <description>CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fasted condition</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: CL-108 (Fed)</title>
            <description>CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fed condition</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: Vicoprofen, Ultracet and Phenergan (Fasted)</title>
            <description>Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fasted condition</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: Vicoprofen, Ultracet and Phenergan (Fed)</title>
            <description>Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time (AUClast) Curve From Time-zero to the Time of the Last Quantifiable Concentration</title>
          <description>Calculated using the linear trapezoidal rule</description>
          <population>ITT population</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hydrocodone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146.2" spread="56.77"/>
                    <measurement group_id="O2" value="151.9" spread="58.79"/>
                    <measurement group_id="O3" value="130.9" spread="47.94"/>
                    <measurement group_id="O4" value="148.5" spread="56.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acetaminophen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.19" spread="5.661"/>
                    <measurement group_id="O2" value="17.85" spread="4.621"/>
                    <measurement group_id="O3" value="18.69" spread="5.186"/>
                    <measurement group_id="O4" value="17.85" spread="4.742"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Promethazine (Number of Participants=19,19,20,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.69" spread="78.87"/>
                    <measurement group_id="O2" value="66.63" spread="67.37"/>
                    <measurement group_id="O3" value="68.54" spread="63.24"/>
                    <measurement group_id="O4" value="74.76" spread="57.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time (AUCinf) Curve From Time-zero Extrapolated to Infinity</title>
        <description>Calculated as:
AUCinf = AUClast + Clast/λz</description>
        <time_frame>0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, and 48 hours post-dose</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: CL-108 (Fasted)</title>
            <description>CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fasted condition</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: CL-108 (Fed)</title>
            <description>CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fed condition</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: Vicoprofen, Ultracet and Phenergan (Fasted)</title>
            <description>Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fasted condition</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: Vicoprofen, Ultracet and Phenergan (Fed)</title>
            <description>Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time (AUCinf) Curve From Time-zero Extrapolated to Infinity</title>
          <description>Calculated as:
AUCinf = AUClast + Clast/λz</description>
          <population>ITT population</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hydrocodone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150.2" spread="57.30"/>
                    <measurement group_id="O2" value="155.8" spread="58.75"/>
                    <measurement group_id="O3" value="134.3" spread="48.20"/>
                    <measurement group_id="O4" value="152.4" spread="56.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Promethazine (Number of Participants=19,18,20,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.92" spread="119.5"/>
                    <measurement group_id="O2" value="60.72" spread="29.74"/>
                    <measurement group_id="O3" value="88.53" spread="100.3"/>
                    <measurement group_id="O4" value="84.13" spread="76.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of AUCinf [AUCExtrap (%)] Based on Extrapolation</title>
        <description>Calculated as:
AUCExtrap (%) = (AUC0-inf - AUC0-last)/AUC0-inf *100</description>
        <time_frame>0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, and 48 hours post-dose</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: CL-108 (Fasted)</title>
            <description>CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fasted condition</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: CL-108 (Fed)</title>
            <description>CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fed condition</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: Vicoprofen, Ultracet and Phenergan (Fasted)</title>
            <description>Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fasted condition</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: Vicoprofen, Ultracet and Phenergan (Fed)</title>
            <description>Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of AUCinf [AUCExtrap (%)] Based on Extrapolation</title>
          <description>Calculated as:
AUCExtrap (%) = (AUC0-inf - AUC0-last)/AUC0-inf *100</description>
          <population>ITT population</population>
          <units>Percentage of AUCExtrap</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hydrocodone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.72" spread="1.72"/>
                    <measurement group_id="O2" value="2.68" spread="1.97"/>
                    <measurement group_id="O3" value="2.65" spread="1.78"/>
                    <measurement group_id="O4" value="2.71" spread="2.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Promethazine (Number of Participants=19,18,20,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.35" spread="7.03"/>
                    <measurement group_id="O2" value="13.54" spread="4.64"/>
                    <measurement group_id="O3" value="15.15" spread="7.86"/>
                    <measurement group_id="O4" value="14.56" spread="6.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to day 72</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment A: CL-108 (Fasted)</title>
          <description>CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fasted condition</description>
        </group>
        <group group_id="E2">
          <title>Treatment B: CL-108 (Fed)</title>
          <description>CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fed condition</description>
        </group>
        <group group_id="E3">
          <title>Treatment C: Vicoprofen, Ultracet and Phenergan (Fasted)</title>
          <description>Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fasted condition</description>
        </group>
        <group group_id="E4">
          <title>Treatment D: Vicoprofen, Ultracet and Phenergan (Fed)</title>
          <description>Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fed condition</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Glossodynia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Oral pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Vessel puncture site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Euphoric mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Commercial Officer</name_or_title>
      <organization>Charleston Laboratories, Inc</organization>
      <phone>561-748-2007</phone>
      <email>cliregulatory@charlestonlabs.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

